Research Articles | Page 37 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes May 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes May 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Nov 2024 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis Jun 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Eat and be healthy: nutritional status in myelodysplastic syndromes Jul 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Mar 2025 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions Jul 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)